Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.36 |
| ▸ | HSD11B2 | P80365 | 3/20 | 0.36 |
| ▸ | IDH1 | O75874 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013882 | 1.00 | EPHX2 (0.45) | EPHX2HSD11B1HSD11B2IDH1FAAH | |
| SCHEMBL1012588 | 0.79 | EPHX2 (0.42) | EPHX2HSD11B1HSD11B2IDH1FAAH | |
| SCHEMBL13667475 | 0.77 | EPHX2 (0.41) | EPHX2HSD11B1HSD11B2IDH1FAAH | |
| SCHEMBL1403242 | 0.75 | MAPK1 (0.37) | EPHX2HSD11B1 | |
| SCHEMBL14260964 | 0.70 | HSD11B1 (0.60) | HSD11B1HSD11B2 | |
| SCHEMBL14260965 | 0.70 | HSD11B1 (0.60) | HSD11B1HSD11B2 | |
| SCHEMBL12887783 | 0.70 | CPB1 (0.46) | EPHX2HSD11B1HSD11B2 | |
| SCHEMBL13661600 | 0.69 | EPHX2 (0.39) | EPHX2FAAHCNR1CNR2 | |
| SCHEMBL6488572 | 0.68 | FAAH (0.38) | EPHX2HSD11B1FAAHCNR1CNR2 | |
| SCHEMBL6488566 | 0.68 | FAAH (0.38) | EPHX2HSD11B1FAAHCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271629-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | claimed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | claimed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | claimed |
| EP-2271629-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | EPHX2 756/4885HSD11B1 2/4885HSD11B2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.